Clinical Trial

The Study of Different Cycles of High-dose Dexamethasone in the Treatment of ITP

Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated April 8, 2025 (before its estimated May 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Primary immune thrombocytopenia is an autoimmune disorder characterised by decreased platelet counts and increased bleeding risk. Corticosteroids have been the standard initial treatment of primary immune thrombocytopenia for more than 30 years. The aim of this randomized controlled trial is to compare the efficacy and safety of high-dose dexamethasone in treating new-diagnosed primary immune thrombocytopenia (ITP) in di-cycle and tri-cycle.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-30.
Trial Details
NCT Number NCT06913374
Lead Sponsor Shandong University
Conditions Thrombocytopenia
Enrollment 118 participants
Start Date 2025-05-01
Primary Completion 2026-05-30 (estimated)
Study Completion 2027-05-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-08